On Oct. 2, 2019, the Masonic Cancer Center and the University of Minnesota (UM) opened a new first-in-human clinical trial for the treatment of advanced solid tumors.

The UM was the third location in the U.S. to open a cell-based cancer immunotherapy clinical trial for the treatment of advanced solid tumors. The multicentered trial investigate the safety and activity of a universal, off-the-shelf natural killer (NK) cell product, based on the groundbreaking NK research done by Jeffrey Miller, MD, of the Masonic Cancer Center and the University of Minnesota Medical School.